Dopamine Receptor Antagonists Pipeline Summary

DelveInsight’s, “Dopamine Receptor Antagonists Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Dopamine Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Dopamine Receptor Antagonists: Understanding

Dopamine Receptor Antagonists: Overview

Dopamine receptor antagonists are drugs that block dopamine receptors, primarily targeting the D2-like family (D2, D3, D4), to modulate dopamine activity in the brain and peripheral systems. They are widely used in the treatment of psychiatric disorders such as schizophrenia and bipolar disorder, as well as for nausea, vomiting, and certain gastrointestinal conditions. These agents work by preventing dopamine from binding to its receptors, thereby reducing overstimulation of dopaminergic pathways. While effective, they may cause side effects like extrapyramidal symptoms or metabolic changes depending on receptor selectivity.

 

Dopamine receptor antagonists typically feature aromatic rings linked to basic nitrogen-containing side chains, allowing them to bind effectively to dopamine receptors especially the D2-like family. Common structural classes include phenothiazines (e.g., chlorpromazine), butyrophenones (e.g., haloperidol), and benzamides (e.g., metoclopramide). These structures mimic dopamine’s shape to fit into the receptor binding pocket but block activation. Their affinity and selectivity depend on substitutions on the aromatic rings and side chains.

 

Dopamine receptor antagonists work by binding to dopamine receptors primarily in the D2-like family (D2, D3, D4) without activating them, thereby blocking dopamine from exerting its effects. This inhibition reduces dopaminergic neurotransmission in brain regions like the mesolimbic pathway, which helps alleviate symptoms of psychosis and other dopamine-related disorders. Their action can also affect motor control, endocrine regulation, and gastrointestinal motility, depending on receptor distribution.

Dopamine receptor antagonists are classified based on the dopamine receptor subtype they block. Dopamine receptors are divided into five subtypes (D1–D5), grouped into two families D1-like and D2-like. Most clinically used antagonists target the D2-like family. Here's a brief explanation of the main types:

• D1 Receptor Antagonists: Dopamine receptor D1, also known as DRD1, is a protein that in humans is encoded by the DRD1 gene. D1 receptors are the most abundant kind of dopamine receptor in the central nervous system.
• D2 Receptor Antagonists: D2 receptor antagonists are drugs that block dopamine D2 receptors to reduce dopaminergic signaling, commonly used to treat psychiatric and gastrointestinal disorders.
• D3 Receptor Antagonists: D3 receptor antagonists block dopamine D3 receptors, primarily in the limbic system, and are being explored for treating schizophrenia, addiction, and cognitive dysfunction.
• D4 Receptor Antagonists: D4 receptor antagonists selectively block dopamine D4 receptors, mainly in the frontal cortex, and are being investigated for potential use in treating attention-related and neuropsychiatric disorders.
• Non-selective D2-like Antagonists (D2/D3/D4): Non-selective D2-like antagonists (D2/D3/D4) block multiple dopamine receptor subtypes to broadly suppress dopaminergic activity, and are widely used in the treatment of schizophrenia, bipolar disorder, and other psychiatric conditions.

Dopamine receptor antagonists serve as key therapeutic targets in managing neuropsychiatric and gastrointestinal disorders by modulating excessive dopaminergic signaling. They are especially effective in treating conditions like schizophrenia, bipolar disorder, nausea, and psychosis, by restoring neurotransmitter balance in affected pathways.

 

"Dopamine Receptor Antagonists Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Dopamine Receptor Antagonists pipeline landscape is provided which includes the overview and Dopamine Receptor Antagonists mechanism of action. The assessment part of the report embraces, in depth Dopamine Receptor Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dopamine Receptor Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dopamine Receptor Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Dopamine Receptor Antagonists.

 

Dopamine Receptor Antagonists Emerging Drugs Chapters

This segment of the Dopamine Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dopamine Receptor Antagonists Emerging Drugs

LYN-005: Lyndra Inc.

LYN-005 is an investigational long-acting oral formulation of risperidone, designed for once-weekly dosing in patients with schizophrenia and related disorders. It utilizes Lyndra’s proprietary LYNX® drug delivery platform, which enables a single capsule to release therapeutic drug levels steadily over an entire week. The therapy aims to improve treatment adherence and reduce relapse risk by eliminating the need for daily medication or injectable long-acting therapies. LYN-005 is currently in late-stage (Phase III) clinical development, with studies demonstrating comparable pharmacokinetics to daily risperidone.

 

NG101: Neurogastrx, Inc.

NG101 is an investigational oral small-molecule dopamine D₂ receptor antagonist (metopimazine mesylate) designed to act peripherally, minimizing central nervous system exposure. It targets the area postrema to reduce nausea and vomiting associated with GLP-1 receptor agonists, without affecting their weight-loss benefits. The drug is also being explored for gastroparesis, a chronic gastrointestinal disorder with limited treatment options. NG101 has demonstrated positive Phase II proof-of-concept data, showing significant reductions in GI adverse events and supporting further clinical development. Currently the drug is in Phase II stage of its development for gastroparesis.

 

NRL-1004: Neurelis, Inc.

NRL-1004 is an investigational intranasal formulation of olanzapine being developed for the rapid treatment of acute agitation episodes associated with schizophrenia and bipolar disorder. It leverages Neurelis’ proprietary Intravail® drug delivery technology, enabling fast, noninvasive absorption through the nasal route. The therapy is designed to provide rapid onset of action in emergency settings while avoiding injections or oral delays. NRL-1004 is currently in early clinical development (Phase I), targeting improved patient compliance and ease of administration in acute CNS conditions. Currently the drug is in Phase I stage of its development.

 

Further product details are provided in the report……..

 

Dopamine Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Dopamine Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dopamine Receptor Antagonists

There are approx. 20+ key companies which are developing the therapies for Dopamine Receptor Antagonists. The companies which have their Dopamine Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Lyndra Inc.

 

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Dopamine Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Dopamine Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dopamine Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dopamine Receptor Antagonists drugs.

 

Dopamine Receptor Antagonists Report Insights

• Dopamine Receptor Antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Dopamine Receptor Antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Dopamine Receptor Antagonists drugs?
• How many Dopamine Receptor Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dopamine Receptor Antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dopamine Receptor Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dopamine Receptor Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

 

Key Players

• Emalex Biosciences
• Neurelis, Inc
• Jazz Pharmaceuticals, Inc.
• Neurogastrx, Inc
• LB pharmaceuticals
• Lyndra Inc.
• Oncoceutics
• Reviva Pharmaceuticals
• Aspartes Pharmaceuticals

 

Key Products

• Ecopipam
• NRL-1004
• ONC 206
• NG101
• LB-102
• LYN-005
• JZP 3507
• Brilaroxazine
• ASP-001